Background: The Coronary Artery Disease Education Questionnaire (CADE-Q) is a validated specific tool used to assess the knowledge and educate coronary patients in cardiac rehabilitation on aspects related to coronary artery disease (CAD). The aim of this study is to translate, cross-culturally adapt and validate from Portuguese to English the Coronary Artery Disease Education Questionnaire (CADE-Q).
Methods: Two independent translations were performed by qualified translators. After back-translation, both versions were reviewed by a committee of experts. A final English version was tested in a pilot study. For the psychometric validation, the tool was administered to 200 Canadian coronary patients enrolled in cardiac rehabilitation (CR). The internal consistency was assessed using Cronbach's alpha, the test-retest reliability using intraclass correlation coefficient (ICC), and the construct validity through factor analysis. Criterion validity of CADE-Q was assessed with regard to patients' characteristics.
Results: Eleven of 19 questions were modified and culturally adapted in the English version. Cronbach's alpha was 0.809 and ICC was 0.846. Factor analysis revealed five factors, all internally consistent and well defined by the items. Criterion validity was supported by significant differences in mean scores by family income (p = 0.02) and educational level (p < 0.001).
Conclusion: The English version of the CADE-Q was demonstrated to have adequate reliability and validity, supporting its use in further studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/2047487312437061 | DOI Listing |
MAGMA
January 2025
Aix Marseille Univ, CNRS, CRMBM, Marseille, France.
Objective: Segmentation of individual thigh muscles in MRI images is essential for monitoring neuromuscular diseases and quantifying relevant biomarkers such as fat fraction (FF). Deep learning approaches such as U-Net have demonstrated effectiveness in this field. However, the impact of reducing neural network complexity remains unexplored in the FF quantification in individual muscles.
View Article and Find Full Text PDFClin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Mol Diagn Ther
January 2025
Istituto Europeo di Oncologia, IRCCS, Via Adamello 16, 20139, Milan, Italy.
Background: Predicting response to targeted cancer therapies increasingly relies on both simple and complex genetic biomarkers. Comprehensive genomic profiling using high-throughput assays must be evaluated for reproducibility and accuracy compared with existing methods.
Methods: This study is a multicenter evaluation of the Oncomine™ Comprehensive Assay Plus (OCA Plus) Pan-Cancer Research Panel for comprehensive genomic profiling of solid tumors.
Am J Cardiovasc Drugs
January 2025
Division of Cardiology, Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
Background: Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.
Methods: This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database.
Pharmacoeconomics
January 2025
Belgian Health Care Knowledge Centre, Brussels, Belgium.
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!